Australia's most trusted
source of pharma news
Saturday, 27 July 2024
Posted 13 May 2024 AM
Pfizer, STADA Pharmaceuticals, and Generic Health will all have their drugs reconsidered at the PBAC's July meeting after accepting the Early Re-Entry resubmission pathway.
It doesn't come as a surprise, as all three pharmas expressed their commitment to working with the reimbursement committee in the sponsors comment section published in the March meeting outcomes.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.